Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in Advanced Lung Adenocarcinoma with Wild-type EGFR
NCT01003899Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2009
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Started Oct 2009; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01003899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01003899.